Docket No.: 63419(52171)

AMENDMENTS TO THE CLAIMS

Claim 1- Claim 26. (Cancelled)

Claim 27. (Previously Presented) A compound of Formula (I)

$$U \xrightarrow{A} G \xrightarrow{E} L \qquad V \qquad OH \qquad V$$

$$X \xrightarrow{R^3} \xrightarrow{R^4} R^4 \qquad R^1 \qquad (I)$$

$$O \xrightarrow{OH} (O)_n$$

wherein

A is a group of formula (II):

wherein Q is sulphur or oxygen, z is CH, and R⁶ is CH₃, CH₂OH or CH₂NH₂,

U is hydrogen,

G-E is selected from the following groups,

wherein R' is methyl,

 R^1 is C_1 - C_4 -alkyl-,

Docket No.: 63419(52171)

L-V-W is a group of formula CH=CH-CH, CH₂-CH₂-CH or CH₂-CH=C, wherein the double bonds may be cis or trans isomers,

n is 0 or 2,

X is oxygen or NH; and

R³ and R⁴ are each methyl,

or a pharmacologically acceptable salt thereof.

Claim 28. (Canceled)

Claim 29. (Previously Presented) A method for treating a patient suffering from or susceptible to breast cancer or epidermoid cancer, comprising administering to the patient a compound of claim 27.

Claim 30. (Currently Amended) The method of claim 29 wherein the patient is identified as suffering from <u>breast cancer or epidermoid</u> cancer and selected for treatment for <u>breast cancer or epidermoid</u> cancer, and the compound is administered to the identified and selected patient.

Claim 31. (Previously Presented) A compound of claim 27, wherein X is oxygen or NH.

Claim 32. (Previously Presented) A compound of claim 27, wherein R¹ is methyl, ethyl or propyl.

Claim 33. (Previously Presented) A compound of claim 27, wherein R^3 and R^4 are methyl groups.

Claim 34. (Previously Presented) A compound of claim 27 wherein A is

Claim 35. (Previously Presented) A pharmaceutical composition comprising a compound of claim 27 or a pharmacologically acceptable salt-thereof.

Claim 36. (Previously Presented) The pharmaceutical composition of claim 35, further comprising one or more carriers, adjuvants, diluents or mixtures thereof.

Claim 37. (Previously Presented) A method for treating a patient suffering from or susceptible to ovarian cancer, lung cancer, prostate cancer, cervix carcinoma, cancer of the bladder or leukemia, comprising administering to the patient a compound of claim 27.